Wiseking Surgical

Wiseking Surgical operates as a subsidiary of Kangji Medical (09997.HK), one of China’s largest minimally invasive surgical instrument manufacturers. Established in December 2021 and headquartered in Hangzhou’s Future Science City, the company focuses exclusively on developing laparoscopic surgical robot systems and associated instruments.

Company Overview

Kangji Medical strategically invested in Wiseking Surgical to expand its product portfolio beyond traditional laparoscopic instruments into the surgical robotics segment. This vertical integration strategy positions Kangji to offer complete minimally invasive surgery solutions—from basic instruments and consumables to advanced robotic systems.

The company’s management team brings extensive experience in robotics development. General Manager Pan Bo leads the commercial and operational functions, while Vice General Manager Zhou Guanshan oversees technical development. The engineering team has successfully built proprietary capabilities across structural design, control systems, core algorithms, and system integration.

Core Products

SR01-200 Four-Arm Laparoscopic Surgical Robot

The SR01-200 represents Wiseking’s flagship commercial product, receiving NMPA approval on April 21, 2025. This milestone made it the first laparoscopic surgical robot to obtain NMPA registration in Zhejiang Province.

The system features a four-arm configuration designed for multi-specialty complex minimally invasive surgeries. Clinical applications span urology, gynecology, and general surgery. The robotic platform underwent registration clinical trials at Zhejiang University School of Medicine’s Sir Run Run Shaw Hospital and the Second Affiliated Hospital.

Key technical specifications include:

• Dual 4K ultra-high-definition displays (3840×2160 resolution)
• Continuous electronic zoom ranging from 0.5x to 16x magnification
• Endoscope diameter reduced 23% compared to market competitors
• Master-slave operation with real-time mapping
• Physiological tremor filtration algorithm
• Reserved interfaces for fluorescence imaging and AI-powered augmented reality navigation

Technology & Innovation

Wiseking has developed proprietary technologies across multiple domains critical to surgical robotics. The company’s technical capabilities include:

Structural Design: Custom mechanical architecture optimized for surgical workspace requirements and collision avoidance between robotic arms during complex procedures.

Control Systems: Self-developed algorithms enabling precise master-slave coordination, ensuring surgical instruments accurately replicate the surgeon’s hand movements in real-time.

Visual Systems: A compact dual-screen display architecture provides immersive 3D visualization while occupying minimal operating room space.

Future Development: The company is actively researching force feedback technology and visual servoing capabilities. Product line expansion plans include three-arm multi-port robots and single-port surgical systems.

Market Presence

Wiseking positions its robotic system differently from premium imports like the da Vinci system. Rather than targeting only top-tier tertiary hospitals, the company aims to penetrate the broader market of prefecture-level Grade A hospitals and even Grade B facilities.

Vice General Manager Zhou Guanshan has stated that domestic surgical robots have significant potential in China’s lower-tier hospital market, potentially achieving adoption rates comparable to conventional laparoscopic surgery as policy restrictions on equipment allocation continue to ease.

The SR01-200 entered mass production in August 2025, with commercial deployment expected to accelerate through Kangji Medical’s established distribution network covering thousands of hospitals nationwide.

Key Milestones

• December 2021: Company established in Hangzhou Future Science City with Kangji Medical investment
• 2024: Completed clinical trial enrollment at Zhejiang University-affiliated hospitals
• April 2025: SR01-200 received NMPA approval (Registration No. 20253010806)
• August 2025: Commenced mass production of SR01-200 system

Frequently Asked Questions

What is Wiseking Surgical’s relationship with Kangji Medical?

Wiseking Surgical operates as a subsidiary (sometimes described as an affiliated company) of Kangji Medical Holdings Limited (09997.HK). Kangji Medical made a strategic investment in Wiseking to vertically integrate surgical robotics into its minimally invasive surgery product portfolio.

Is the SR01-200 approved for clinical use?

Yes. The SR01-200 received NMPA (National Medical Products Administration) approval on April 21, 2025, with registration certificate number 20253010806. It is approved for laparoscopic procedures in urology, gynecology, and general surgery.

How does the SR01-200 compare to imported surgical robots?

The SR01-200 offers comparable four-arm functionality with 4K visualization and tremor filtration, positioning it as a domestic alternative with potential cost advantages. The system is designed to address the broader Chinese hospital market beyond top-tier institutions that currently dominate da Vinci installations.